Drug Search Results
Using advanced filters...
Advanced Search [+]

8MW2311

Alternative Names: 8MW2311, 8-MW2311
Latest Update: 2024-11-20
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: IL2 Agonist

Novel Mechanism: Yes

Modality: N/A

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Mabwell (Shanghai) Bioscience
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for 8MW2311

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

8MW2311-2022-CP101

P2

Suspended

Oncology Solid Tumor Unspecified

2026-03-01

Recent News Events

Date

Type

Title